Search Results

There are 1818 results for: content related to: Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis

  1. Posaconazole: when and how? The clinician’s view

    Mycoses

    Volume 55, Issue 2, March 2012, Pages: 110–122, Aspasia Katragkou, Fotini Tsikopoulou, Emmanuel Roilides and Theoklis E. Zaoutis

    Version of Record online : 18 JUL 2011, DOI: 10.1111/j.1439-0507.2011.02061.x

  2. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection

    Mycoses

    Volume 59, Issue 11, November 2016, Pages: 726–733, Jong Hun Kim, Russell J. Benefield and Kali Ditolla

    Version of Record online : 9 JUL 2016, DOI: 10.1111/myc.12524

  3. Review of the New Delayed-Release Oral Tablet and Intravenous Dosage Forms of Posaconazole

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 35, Issue 2, February 2015, Pages: 208–219, Anthony J. Guarascio and Douglas Slain

    Version of Record online : 3 FEB 2015, DOI: 10.1002/phar.1533

  4. Supersaturation and Precipitation of Posaconazole upon Entry in the Upper Small Intestine in Humans

    Journal of Pharmaceutical Sciences

    Bart Hens, Joachim Brouwers, Maura Corsetti and Patrick Augustijns

    Version of Record online : 27 OCT 2015, DOI: 10.1002/jps.24690

  5. You have free access to this content
    Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview

    British Journal of Clinical Pharmacology

    Volume 70, Issue 4, October 2010, Pages: 471–480, Hans-Peter Lipp

    Version of Record online : 14 SEP 2010, DOI: 10.1111/j.1365-2125.2010.03680.x

  6. Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin

    The Journal of Clinical Pharmacology

    Volume 51, Issue 1, January 2011, Pages: 84–92, Dr Gopal Krishna, Dr Donna Vickery, Lei Ma, Dr Xin Yu, Dr Carl Noren, Dr Edward Power, Dr Eric Beresford and Dr Matthew Medlock

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270009360982

  7. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections

    International Journal of Clinical Practice

    Volume 58, Issue 6, June 2004, Pages: 612–624, R. Herbrecht

    Version of Record online : 24 JUN 2004, DOI: 10.1111/j.1368-5031.2004.00167.x

  8. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis

    British Journal of Dermatology

    Volume 166, Issue 2, February 2012, Pages: 389–398, B. Elewski, R. Pollak, S. Ashton, P. Rich, J. Schlessinger and A. Tavakkol

    Version of Record online : 6 DEC 2011, DOI: 10.1111/j.1365-2133.2011.10660.x

  9. Optimising absorption of posaconazole

    Mycoses

    Volume 54, Issue 6, November 2011, Pages: e775–e779, Myke R. Green and Joseph E. Woolery

    Version of Record online : 25 MAY 2011, DOI: 10.1111/j.1439-0507.2011.02020.x

  10. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers

    Journal of Clinical Pharmacy and Therapeutics

    Volume 34, Issue 3, June 2009, Pages: 301–311, A. Moton, G. Krishna and Z. Wang

    Version of Record online : 15 APR 2009, DOI: 10.1111/j.1365-2710.2009.01055.x

  11. Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 2, February 2005, Pages: 185–192, Dr R. Courtney, Dr A. Sansone, Dr W. Smith, Dr T. Marbury, Dr P. Statkevich, Ms M. Martinho, Dr M. Laughlin and Dr S. Swan

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270004271402

  12. Posaconazole Therapeutic Drug Monitoring in the Real-life Setting: A Single-Center Experience and Review of the Literature

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 10, October 2013, Pages: 1117–1125, Barbara N. Gross, Gabriele Ihorst, Manfred Jung, Ralph Wäsch and Monika Engelhardt

    Version of Record online : 17 JUL 2013, DOI: 10.1002/phar.1328

  13. Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation

    Transplant Infectious Disease

    Volume 15, Issue 5, October 2013, Pages: 449–456, W.J. Heinz, H. Einsele, A. Helle-Beyersdorf, J. Zirkel, A. Grau, D. Schirmer, U. Lenker and H. Klinker

    Version of Record online : 25 JUL 2013, DOI: 10.1111/tid.12108

  14. Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections

    Mycoses

    Volume 58, Issue 6, June 2015, Pages: 362–367, Chiara Cattaneo, Annafranca Panzali, Angela Passi, Erika Borlenghi, Cinzia Lamorgese, Marta Petullà, Alessandro Re, Luigi Caimi and Giuseppe Rossi

    Version of Record online : 23 APR 2015, DOI: 10.1111/myc.12326

  15. Management of Drug Interaction between Posaconazole and Sirolimus in Patients Who Undergo Hematopoietic Stem Cell Transplant

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 35, Issue 6, June 2015, Pages: 578–585, Eunah Cho, Holly Chan, Huan (Mark) Nguyen, Sepideh Shayani, Ryotaro Nakamura and Doreen Pon

    Version of Record online : 3 JUN 2015, DOI: 10.1002/phar.1600

  16. Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

    Clinical Pharmacology & Therapeutics

    Volume 88, Issue 1, July 2010, Pages: 115–119, S H Jang, P M Colangelo and J V S Gobburu

    Version of Record online : 26 MAY 2010, DOI: 10.1038/clpt.2010.64

  17. Posaconazole Pharmacokinetics in a 2-Year-Old Boy with Rhino-Cerebral-Orbital Zygomycosis

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 1, January 2013, Pages: e1–e8, Eric F. Egelund, Tosha A. Egelund, John S. Ng, Sarah K. Wassil and Charles A. Peloquin

    Version of Record online : 10 JAN 2013, DOI: 10.1002/phar.1172

  18. You have free access to this content
    Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States

    Value in Health

    Volume 12, Issue 5, July/August 2009, Pages: 666–673, Amy K. O'Sullivan, Ankur Pandya, George Papadopoulos, David Thompson, Amelia Langston, John Perfect and Milton C. Weinstein

    Version of Record online : 12 JAN 2009, DOI: 10.1111/j.1524-4733.2008.00486.x

  19. You have free access to this content
    HPLC/UV or bioassay: two valid methods for posaconazole quantification in human serum samples

    Clinical Microbiology and Infection

    Volume 18, Issue 12, December 2012, Pages: 1229–1235, E. Cendejas-Bueno, A. Forastiero, J. L. Rodriguez-Tudela, M. Cuenca-Estrella and A. Gomez-Lopez

    Version of Record online : 22 DEC 2011, DOI: 10.1111/j.1469-0691.2011.03732.x

  20. You have free access to this content
    Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014

    Internal Medicine Journal

    Volume 44, Issue 12b, December 2014, Pages: 1364–1388, M. M. Chau, D. C. M. Kong, S. J. van Hal, K. Urbancic, J. A. Trubiano, M. Cassumbhoy, J. Wilkes, C. M. Cooper, J. A. Roberts, D. J. E. Marriott and L. J. Worth

    Version of Record online : 8 DEC 2014, DOI: 10.1111/imj.12600